Apollomics Class A Stock Performance
| APLM Stock | 19.87 1.87 10.39% |
On a scale of 0 to 100, Apollomics holds a performance score of 8. The firm shows a Beta (market volatility) of -1.3, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Apollomics are expected to decrease by larger amounts. On the other hand, during market turmoil, Apollomics is expected to outperform it. Please check Apollomics' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to make a quick decision on whether Apollomics' price patterns will revert.
Risk-Adjusted Performance
Fair
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Apollomics Class A are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of very conflicting essential indicators, Apollomics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 3.89 | Five Day Return (5.03) | Year To Date Return (3.11) | Ten Year Return (98.11) | All Time Return (98.11) |
Last Split Factor 1:100 | Last Split Date 2024-11-25 |
1 | 12 Health Care Stocks Moving In Thursdays Intraday Session | 10/30/2025 |
2 | Is Apollomics Inc. stock positioned for long term growth - Quarterly Risk Review Weekly Stock Breakout Alerts - newser.com | 11/04/2025 |
3 | Apollomics Reports First Half 2025 Financial Results | 12/22/2025 |
4 | Apollomics Upgraded at Wall Street Zen | 01/20/2026 |
| Begin Period Cash Flow | 32.1 M | |
| Total Cashflows From Investing Activities | 6 M |
Apollomics | Build AI portfolio with Apollomics Stock |
Apollomics Relative Risk vs. Return Landscape
If you would invest 1,411 in Apollomics Class A on October 29, 2025 and sell it today you would earn a total of 576.00 from holding Apollomics Class A or generate 40.82% return on investment over 90 days. Apollomics Class A is currently generating 0.9234% in daily expected returns and assumes 8.6434% risk (volatility on return distribution) over the 90 days horizon. In different words, 77% of stocks are less volatile than Apollomics, and 82% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Apollomics Target Price Odds to finish over Current Price
The tendency of Apollomics Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 19.87 | 90 days | 19.87 | about 34.4 |
Based on a normal probability distribution, the odds of Apollomics to move above the current price in 90 days from now is about 34.4 (This Apollomics Class A probability density function shows the probability of Apollomics Stock to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days Apollomics Class A has a beta of -1.3. This suggests as returns on its benchmark rise, returns on holding Apollomics Class A are expected to decrease by similarly larger amounts. On the other hand, during market turmoils, Apollomics is expected to outperform its benchmark. Additionally Apollomics Class A has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Apollomics Price Density |
| Price |
Predictive Modules for Apollomics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Apollomics Class A. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Apollomics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Apollomics is not an exception. The market had few large corrections towards the Apollomics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Apollomics Class A, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Apollomics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.22 | |
β | Beta against Dow Jones | -1.3 | |
σ | Overall volatility | 3.96 | |
Ir | Information ratio | -0.04 |
Apollomics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Apollomics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Apollomics Class A can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Apollomics Class A is way too risky over 90 days horizon | |
| Apollomics Class A appears to be risky and price may revert if volatility continues | |
| Apollomics Class A has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 198 K. Net Loss for the year was (53.86 M) with profit before overhead, payroll, taxes, and interest of 198 K. | |
| Apollomics generates negative cash flow from operations | |
| Apollomics Class A has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Apollomics Upgraded at Wall Street Zen |
Apollomics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Apollomics Stock often depends not only on the future outlook of the current and potential Apollomics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Apollomics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 926.5 K | |
| Cash And Short Term Investments | 9.8 M |
Apollomics Fundamentals Growth
Apollomics Stock prices reflect investors' perceptions of the future prospects and financial health of Apollomics, and Apollomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Apollomics Stock performance.
| Return On Equity | -2.34 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | 10.07 % | ||||
| Current Valuation | 37.23 M | ||||
| Shares Outstanding | 2.14 M | ||||
| Price To Book | 8.12 X | ||||
| Price To Sales | 5.57 X | ||||
| Revenue | 198 K | ||||
| Gross Profit | 198 K | ||||
| EBITDA | (41.05 M) | ||||
| Net Income | (53.86 M) | ||||
| Total Debt | 966 K | ||||
| Book Value Per Share | 4.41 X | ||||
| Cash Flow From Operations | (28.74 M) | ||||
| Earnings Per Share | (52.80) X | ||||
| Market Capitalization | 44.92 M | ||||
| Total Asset | 13.1 M | ||||
| Retained Earnings | (700.82 M) | ||||
| Working Capital | 2.87 M | ||||
About Apollomics Performance
By examining Apollomics' fundamental ratios, stakeholders can obtain critical insights into Apollomics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Apollomics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (5.45) | (5.18) | |
| Return On Capital Employed | (8.50) | (8.08) | |
| Return On Assets | (4.73) | (4.49) | |
| Return On Equity | (12.73) | (12.10) |
Things to note about Apollomics Class A performance evaluation
Checking the ongoing alerts about Apollomics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Apollomics Class A help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Apollomics Class A is way too risky over 90 days horizon | |
| Apollomics Class A appears to be risky and price may revert if volatility continues | |
| Apollomics Class A has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 198 K. Net Loss for the year was (53.86 M) with profit before overhead, payroll, taxes, and interest of 198 K. | |
| Apollomics generates negative cash flow from operations | |
| Apollomics Class A has a poor financial position based on the latest SEC disclosures | |
| Latest headline from thelincolnianonline.com: Apollomics Upgraded at Wall Street Zen |
- Analyzing Apollomics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Apollomics' stock is overvalued or undervalued compared to its peers.
- Examining Apollomics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Apollomics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Apollomics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Apollomics' stock. These opinions can provide insight into Apollomics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Apollomics Class A. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in industry. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Apollomics. If investors know Apollomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Apollomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (52.80) | Revenue Per Share | Quarterly Revenue Growth 2.623 | Return On Assets | Return On Equity |
The market value of Apollomics Class A is measured differently than its book value, which is the value of Apollomics that is recorded on the company's balance sheet. Investors also form their own opinion of Apollomics' value that differs from its market value or its book value, called intrinsic value, which is Apollomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Apollomics' market value can be influenced by many factors that don't directly affect Apollomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Apollomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Apollomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Apollomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.